Skip to main content
Monday, November 16, 2026Nov 16

FDA grants speedy approval to Eli Lilly’s weight-loss pill for obesity

This photo provided by Eli Lilly in April 2026 shows manufacturing of the company's weight loss pill, Foundayo, at a plant in Carolina, Puerto Rico. (Eli Lilly via AP)
This photo provided by Eli Lilly in April 2026 shows manufacturing of the company's weight loss pill, Foundayo, at a plant in Carolina, Puerto Rico. (Eli Lilly via AP)


Federal regulators on Wednesday approved Eli Lilly’s new weight-loss pill, a second daily oral medication to treat obesity and other weight-related conditions.

The Food and Drug Administration granted expedited approval to orforglipron, a GLP-1 drug that works like widely used injectable medications to mimic a natural hormone that controls appetite and feelings of fullness.

The drug, which will be branded as Foundayo, is expected to begin shipping Monday. The company said people with insurance may be able to get the drug starting at $25 per month with a Lilly discount card. Prices for people paying cash will range between $149 per month to $349 per month, depending on the dose.

The new pill joins drugmaker Novo Nordisk’s oral Wegovy pill, which has spurred more than 600,000 prescriptions in the United States since it was approved in December.